Dyadic DYAI Stock
Dyadic Price Chart
Dyadic DYAI Financial and Trading Overview
| Dyadic stock price | 1.76 USD |
| Previous Close | 2.04 USD |
| Open | 2.06 USD |
| Bid | 0 USD x 3000 |
| Ask | 0 USD x 1000 |
| Day's Range | 2.01 - 2.08 USD |
| 52 Week Range | 1.12 - 3.56 USD |
| Volume | 12.48K USD |
| Avg. Volume | 36.79K USD |
| Market Cap | 58.49M USD |
| Beta (5Y Monthly) | 0.682042 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.24 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6 USD |
DYAI Valuation Measures
| Enterprise Value | 47.04M USD |
| Trailing P/E | N/A |
| Forward P/E | 25.375 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 17.94105 |
| Price/Book (mrq) | 5.4133334 |
| Enterprise Value/Revenue | 14.429 |
| Enterprise Value/EBITDA | N/A |
Trading Information
Dyadic Stock Price History
| Beta (5Y Monthly) | 0.682042 |
| 52-Week Change | -27.49% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 3.56 USD |
| 52 Week Low | 1.12 USD |
| 50-Day Moving Average | 1.97 USD |
| 200-Day Moving Average | 1.77 USD |
DYAI Share Statistics
| Avg. Volume (3 month) | 36.79K USD |
| Avg. Daily Volume (10-Days) | 18.61K USD |
| Shares Outstanding | 28.81M |
| Float | 18.71M |
| Short Ratio | 19.84 |
| % Held by Insiders | 30.29% |
| % Held by Institutions | 16.12% |
| Shares Short | 441.8K |
| Short % of Float | 2.18% |
| Short % of Shares Outstanding | 1.53% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -251.54% |
| Operating Margin (ttm) | -288.36% |
| Gross Margin | 24.98% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -37.49% |
| Return on Equity (ttm) | -60.29% |
Income Statement
| Revenue (ttm) | 3.26M USD |
| Revenue Per Share (ttm) | 0.11 USD |
| Quarterly Revenue Growth (yoy) | 50.79% |
| Gross Profit (ttm) | 807.11K USD |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | -8200037 USD |
| Diluted EPS (ttm) | -0.27 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 11.74M USD |
| Total Cash Per Share (mrq) | 0.41 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 6.829 |
| Book Value Per Share (mrq) | 0.375 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -7420330 USD |
| Levered Free Cash Flow (ttm) | -4328375 USD |
Profile of Dyadic
| Country | United States |
| State | FL |
| City | Jupiter |
| Address | 140 Intracoastal Pointe Drive |
| ZIP | 33477-5094 |
| Phone | 561 743 8333 |
| Website | https://www.dyadic.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. It utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus-like particles, protein antigens, ferritin nanoparticles, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to demonstrate the safety in humans of a protein produced from C1-cell protein production platform. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; and strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U., as well as co-development and marketing agreement with Fermbox Bio Inc to design, Develop, and commercialize animal free alternative proteins and biomaterials The company was founded in 1979 and is headquartered in Jupiter, Florida.
Q&A For Dyadic Stock
What is a current DYAI stock price?
Dyadic DYAI stock price today per share is 1.76 USD.
How to purchase Dyadic stock?
You can buy DYAI shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Dyadic?
The stock symbol or ticker of Dyadic is DYAI.
Which industry does the Dyadic company belong to?
The Dyadic industry is Biotechnology.
How many shares does Dyadic have in circulation?
The max supply of Dyadic shares is 28.97M.
What is Dyadic Price to Earnings Ratio (PE Ratio)?
Dyadic PE Ratio is now.
What was Dyadic earnings per share over the trailing 12 months (TTM)?
Dyadic EPS is -0.24 USD over the trailing 12 months.
Which sector does the Dyadic company belong to?
The Dyadic sector is Healthcare.
Dyadic DYAI included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Capital Market Composite RCMP | 114.55 USD — |
-2.27
|
— — | 114.09 USD — | 116.72 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}